Clin Endosc.  2022 Mar;55(2):210-212. 10.5946/ce.2022.063.

Fecal Calprotectin as a Surrogate Marker for Mucosal Healing After Initiating the Therapeutic Anti-Tubercular Trial

• Aniwan S

• KMID: 2527563
• DOI: http://doi.org/10.5946/ce.2022.063

Reference

1. Ran Z, Wu K, Matsuoka K, et al. Asian Organization for Crohn’s and Colitis and Asia Pacific Association of Gastroenterology practice recommendations for medical management and monitoring of inflammatory bowel disease in Asia. J Gastroenterol Hepatol. 2021; 36:637–645.

2. Jin XJ, Kim JM, Kim HK, et al. Histopathology and TB-PCR kit analysis in differentiating the diagnosis of intestinal tuberculosis and Crohn’s disease. World J Gastroenterol. 2010; 16:2496–2503.

3. Lu Y, Chen Y, Peng X, et al. Development and validation of a new algorithm model for differential diagnosis between Crohn’s disease and intestinal tuberculosis: a combination of laboratory, imaging and endoscopic characteristics. BMC Gastroenterol. 2021; 21:291.

4. Limsrivilai J, Shreiner AB, Pongpaibul A, et al. Meta-analytic bayesian model for differentiating intestinal tuberculosis from crohn’s disease. Am J Gastroenterol. 2017; 112:415–427.

5. Xu H, Li Y, Qian JM. A meta-analysis of the accuracy of interferon-γ release assays in differentiating intestinal tuberculosis from Crohn’s disease in Asia. Zhonghua Nei Ke Za Zhi. 2016; 55:535–540.

6. Zhao Y, Xu M, Chen L, Liu Z, Sun X. Levels of TB-IGRA may help to differentiate between intestinal tuberculosis and Crohn’s disease in patients with positive results. Therap Adv Gastroenterol. 2020; 13:1756284820922003.

7. Limsrivilai J, Pausawasdi N. Intestinal tuberculosis or Crohn’s disease: a review of the diagnostic models designed to differentiate between these two gastrointestinal diseases. Intest Res. 2021; 19:21–32.

8. Limsrivilai J, Lee CK, Prueksapanich P, et al. Validation of models using basic parameters to differentiate intestinal tuberculosis from Crohn’s disease: a multicenter study from Asia. PLoS One. 2020; 15:e0242879.

9. Jo HH, Kim EY, Jung JT, et al. Value of Fecal Calprotectin Measurement During the Initial Period of Therapeutic Anti-tubercular trial. Clin Endosc. 2022; 55:256–262.

10. Sharma V, Verma S, Kumar MP, et al. Serial measurements of faecal calprotectin may discriminate intestinal tuberculosis and Crohn’s disease in patients started on antitubercular therapy. Eur J Gastroenterol Hepatol. 2021; 33:334–338.